Documents sudden leadership instability at FDA’s drug evaluation division, raising questions about regulatory continuity and institutional governance. Examines implications for pharmaceutical oversight and public health policy consistency.
FDA Drug Evaluation Chief Richard Pazdur to Retire Weeks After Appointment
Documents sudden leadership instability at FDA’s drug evaluation division, raising questions about regulatory continuity and institutional governance. Examines implications for pharmaceutical oversight and public health policy consistency. Read the full…